🇺🇸 FDA
Patent

US 9994584

Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid

granted A61KA61K31/496

Quick answer

US patent 9994584 (Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid) held by Lixte Biotechnology, Inc. expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Lixte Biotechnology, Inc.
Grant date
Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/496